Avidity Biosciences, Inc.: Business Overview, Financials & Competitive Analysis
Avidity Biosciences, Inc. scores 8/10 on the AskCyborg Cyborg Score (Strong). Innovative AOC platform addressing underserved neuromuscular disease markets, validated by major pharma acquisition and advancing clinical pipeline. Novartis's $12 billion acquisition validates Avidity's platform technology and pipeline potential. Analyst consensus rates RNA as "Buy" with an average 12-month price target of $69.26. Revenue growth remains modest at $10.90M (2024).
What is Avidity Biosciences, Inc.'s industry? Avidity Biosciences, Inc. (aviditybiosciences.com) operates in Biopharmaceutical / RNA Therapeutics. AskCyborg classifies Avidity Biosciences, Inc. under Biopharmaceutical / RNA Therapeutics in its company registry.
Avidity Biosciences is a biopharmaceutical company developing antibody oligonucleotide conjugates (AOCs), a novel class of RNA therapeutics that combine monoclonal antibody specificity with RNA precision to target pre...
Cyborg Score thesis
Innovative AOC platform addressing underserved neuromuscular disease markets, validated by major pharma acquisition and advancing...
Read the full analyst-debate transcript →Get the Latest Avidity Biosciences, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeAvidity Biosciences, Inc. Overview
Pro stress-test →Avidity Biosciences is a biopharmaceutical company developing antibody oligonucleotide conjugates (AOCs), a novel class of RNA therapeutics that combine monoclonal antibody specificity with RNA precision to target previously untreatable diseases. The company is being acquired by Swiss pharma giant Novartis in a $12 billion all-cash transaction at $72 per share.
Strategic Profile
Pro stress-test →Avidity's pipeline includes three registrational clinical programs for muscular dystrophies (myotonic, facioscapulohumeral, and Duchenne) plus precision cardiology candidates for rare genetic cardiomyopathies. The AOC platform represents a differentiated approach to RNA delivery with potential for multiple indications across muscle and cardiac diseases.
Competitive Landscape
Pro stress-test →Avidity competes in the RNA therapeutics space against established players like Alnylam Pharmaceuticals and Arrowhead Pharmaceuticals, plus emerging biotech innovators. Its differentiated AOC platform targeting previously untreatable diseases provides competitive advantage. The Novartis acquisition removes it from independent competition and positions it within a large pharma ecosystem.
Industry Context
Avidity Biosciences, Inc. operates in Biopharmaceutical / RNA Therapeutics.
Key facts
Founded: 2012 · Headquarters: San Diego, US · Revenue: $10.9M · Market cap: $11.0B